Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).| Product Name | LSD1 |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | Amine oxidase (flavin containing) domain 2 antibody Amine oxidase, flavin containing, 2 antibody AOF2 antibody BHC110 antibody BRAF35 HDAC complex protein BHC110 antibody BRAF35-HDAC complex protein BHC110 antibody BRAF35/HDAC complex, 110-kD subunit antibody CPRF antibody EC1 antibody FAD binding protein BRAF35 HDAC complex, 110 kDa subunit antibody Flavin-containing amine oxidase domain-containing protein 2 antibody KDM 1 antibody KDM1 antibody Kdm1a antibody KDM1A_HUMAN antibody KIAA0601 antibody LSD 1 antibody LSD1 antibody Lysine (K) specific demethylase 1 antibody Lysine (K) specific demethylase 1A antibody Lysine demethylase 1A antibody Lysine specific histone demethylase 1 antibody Lysine specific histone demethylase 1A antibody Lysine-specific demethylase 1 antibody Lysine-specific demethylase 1A antibody Lysine-specific histone demethylase 1A antibody |
| Product description | Histone methylation regulates chromatin structure and transcription and maintains an epigenetic state of the cell. Histone methylation is dynamically regulated by histone methylases and demethylases. Lysine-specific histone demethylase 1 (LSD1), also designated BHC110, is a flavin-dependent amine oxidase which catalyzes the removal of one or two methyl groups from the methyl-lysine-4 side chain of Histone H3. The LSD1 protein contains a SWIRM domain, a FAD-binding motif and an amine oxidase domain. Association with CoREST, a SANT domain-containing corepressor, positively regulates LSD1. CoREST mediates the demethylation ability of LSD1 and protects it from proteasomal degradation in vivo. PHF21A (also designated BCH80), a PHD domain-containing protein, inhibits activity of LSD1/CoREST mediated de-methylation. The LSD1 protein also co-localizes with the androgen receptor in human prostate tumor cells and in unaffected prostate cells, stimulating androgen-receptor-dependent transcription. |
| Immunogen | Peptide |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBICCIHC |
| WB:1:500-1,000 ICC:1:500-1:2,000 IHC:1:50-1:200 FC:1:50-1:100 |
|
| Species Reactivity | HumanMouseRat |
| Concentration | 1mg/ml |
| Alternative Names | Amine oxidase (flavin containing) domain 2 antibody
Amine oxidase flavin containing 2 antibody AOF2 antibody BHC110 antibody BRAF35 HDAC complex protein BHC110 antibody BRAF35-HDAC complex protein BHC110 antibody BRAF35/HDAC complex 110-kD subunit antibody CPRF antibody EC1 antibody FAD binding protein BRAF35 HDAC complex 110 kDa subunit antibody Flavin-containing amine oxidase domain-containing protein 2 antibody KDM 1 antibody KDM1 antibody Kdm1a antibody KDM1A_HUMAN antibody KIAA0601 antibody LSD 1 antibody LSD1 antibody Lysine (K) specific demethylase 1 antibody Lysine (K) specific demethylase 1A antibody Lysine demethylase 1A antibody Lysine specific histone demethylase 1 antibody Lysine specific histone demethylase 1A antibody Lysine-specific demethylase 1 antibody Lysine-specific demethylase 1A antibody Lysine-specific histone demethylase 1A antibody |
|---|---|
| Molecular Weight(MW) | 110 kDa |
| Cellular Localization | Nucleus. |
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).
Application
Fig10: Flow cytometric analysis of K562 cells with LSD1 antibody at 1/100 dilution (red) compared with an unlabelled control (cells without incubation with primary antibody; black).| Positive Control | PC-12, SiHa, A431, HepG2, SH-SY-5Y, rat kidney tissue, human colon cancer tissue, human spleen tissue, human kidney tissue, mouse cerebellum tissue, K562. |
|---|---|
| Application Notes | WB:1:500-1,000 ICC:1:500-1:2,000 IHC:1:50-1:200 FC:1:50-1:100 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | 1*TBS (pH7.4), 0.5%BSA, 50%Glycerol. Preservative: 0.05% Sodium Azide. |
